NICE's Zinbryta recommendation 'great news for people with relapsing MS'

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending that Zinbryta (daclizumab) be made available on the UK’s National Health Service (NHS) for adult patients living with relapsing-remitting multiple sclerosis (RRMS).

In its recommendation, the NICE suggests that the targeted, humanized monoclonal antibody with non-depleting and reversible effects on the immune system be considered for active RRMS patients who have failed to respond to first-line, disease-modifying therapy, or patients with rapidly evolving severe (RES) RRMS.

"This is an effective medicine and the first that people can take by self-injecting once a month"